Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen?

Linvoseltamab is the fourth FDA approved bispecific antibody for the treatment of RRMM in patients who have received four or more lines of therapy. Cross-trial comparisons have suggested that linvoseltamab has comparable to slightly better efficacy compared with other agents. Linvoseltamab offers an optimized dosing regimen with a favorable CRS profile. Further real-world data are needed to understand linvoseltamab's role within the MM treatment paradigm.